Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 30.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 30.0 Contact Hours.

Mini Symposium: Designated for a maximum of 4.5 AMA PRA Category 1 Credits™ (4.5 Contact Hours)

Main Symposium: Designated for a maximum of 25.5 AMA PRA Category 1 Credits™ (25.5 Contact Hours)

This activity provides Category I CME and self-assessment credits toward Part 2 of the ABS MOC Program. For more information, please visit www.absurgery.org

This activity is supported by educational grants from AbbVie, Astellas, AstraZeneca, Celgene Corporation, Genentech, Genomic Health, Inc., Eisai, Inc., Incyte, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., and Pfizer.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

34th Annual Miami Breast Cancer Conference Resources

34th Annual Miami Breast Cancer Conference®


PER Pulse™ Recap

Resources

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series
Earn up to 2.0 AMA PRA Category 1 Credits

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™ is an online continuing medical education (CME)‒certified activity.

PER Pulse™ Recap
PER Pulse™ Recaps for the 34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™ focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of expert perspective on case management decisions is provided in these summaries.


PER Pulse™ Recap

PER Pulse™ Recap



1 of 3
PER Pulse™ Recap

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™ is a series of short video interviews with faculty from the live 34th Annual Miami Breast Cancer Conference®, who address a variety of questions via discussion of clinical vignettes that were presented at the Conference. The online activity features discussion on the following:

  • Neoadjuvant therapy for early-stage, HER2-positive breast cancer, by Debu Tripathy, MD
  • Immunotherapy in breast cancer, by Elizabeth Mittendorf, MD, PhD Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Tripathy, during which he discussed:

  • His approach toward neoadjuvant therapy and follow-up for a 57-year-old female who was diagnosed with a grade II infiltrating ductal cancer, HER2-positive breast cancer (clinical size 3.8 cm).
  • Key components of neoadjuvant therapy response evaluation, including examination at every cycle of chemotherapy to detect progression and pathologic assessment at the time of surgery (eg, with residual cancer burden calculator)
  • Factors that influence degree of response to neoadjuvant therapy and how it translates into conversion from mastectomy to breast conserving surgery eligibility, including tumor location, body type, size of breast, and patient preference
  • His perspectives on data showing increased rates of pathologic complete response (pCR), but not survival, when lapatinib was added to neoadjuvant trastuzumab-chemotherapy
  • Clinical questions being addressed by the KATHERINE trial of adding TDM1 to adjuvant therapy to reduce risk of recurrence for patients who did not achieve pCR after standard neoadjuvant therapy


2 of 3
PER Pulse™ Recap

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™ is a series of short video interviews with faculty from the live 34th Annual Miami Breast Cancer Conference®, who address a variety of questions via discussion of clinical vignettes that were presented at the Conference. The online activity features discussion on the following:

  • Neoadjuvant therapy for early-stage, HER2-positive breast cancer, by Debu Tripathy, MD
  • Immunotherapy in breast cancer, by Elizabeth Mittendorf, MD, PhD Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Mittendorf, during which she discussed:

  • Her approach toward discussing the status of immunotherapy with a 47-year-old female patients with metastatic triple-negative breast cancer who has no family history of breast or ovarian cancer and no evidence of deleterious mutations by breast cancer susceptibility gene panel testing
  • Recent data on the immunogenicity of breast cancer that provide rationale for the use of immunotherapy.
  • Strategies being investigated to augment the immunogenicity/T-cell infiltrate in breast cancer
  •  

3 of 3
PER Pulse™ Recap

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™ is a series of short video interviews with faculty from the live 34th Annual Miami Breast Cancer Conference®, who address a variety of questions via discussion of clinical vignettes that were presented at the Conference. The online activity features discussion on the following:

  • Neoadjuvant therapy for early-stage, HER2-positive breast cancer, by Debu Tripathy, MD
  • Immunotherapy in breast cancer, by Elizabeth Mittendorf, MD, PhD Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Mittendorf, during which she discussed:

  • Data from phase I trials of checkpoint inhibitor therapy for advanced triple-negative breast cancer
  • How outcomes observed in trials of checkpoint inhibitors for breast cancer compare with those observed for other solid tumor types
  • Progress made toward identifying patients with breast cancer who are most likely to benefit from checkpoint inhibitor therapy
  • Rationale for using checkpoint inhibition in combination with other therapeutics







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By